Celcuity, which is developing live cell diagnostic tests for cancer patients, announced terms for its IPO on Thursday.
The Minneapolis, MN-based company plans to raise $18 million by offering 2 million shares at a price range of $8 to $10. At the midpoint of the proposed range, Celcuity would command a fully diluted market value of $85 million.
Celcuity was founded in 2011 and plans to list on the Nasdaq under the symbol CELC. Craig-Hallum Capital Group is the sole bookrunner on the deal.
